retatrutide nonalcoholic steatohepatitis trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Xia & He Publishing

Microdosing GLP-1 GIP B12 for longevity A separate and distinct use case has emerged for tirzepatide and GLP-1 class agents: microdosing for metabolic health, anti-inflammatory effects, and longevity, independent of weight loss goals

LL-37 disrupts microbial membranes and modulates adaptive immunity

11 Patients likely to benefit from these medicines who do not meet the criteria for funded treatment are those: 11 With CVD (or five-year CVD risk 15%), renal disease or heart failure * with a HbA 1c 75 mmol/mol do not usually require a reduction in insulin or sulfonylurea, unless they have a history of hypoglycaemia

Hughes, S., & Neumiller, J

More receptors is not automatically a free upgrade It is tempting to think: more receptors = better drug But that is too simple